Rho Celebrates 25th Anniversary
Chapel Hill, NC
October 24, 2009 marked the 25th Anniversary for Rho, a Chapel Hill based contract research organization. Established in 1984, Rho began as a small, family run business in the basement of the home of Ron and Mary Helms. Since then, it has rapidly developed into a large family owned company that conducts business with some of the most dynamic pharmaceutical, biotech, and medical device companies in the U.S.
During the past 25 years, Rho has acquired a strong commercial and federal customer base because of its customer service and scientific expertise. Consulting to the FDA, rescuing poorly executed pivotal trials, authoring and coauthoring 252 articles, 89 presentations, and 82 abstracts are
among of Rho’s accomplishments.
Rho contributes to the success of pharmaceutical, medical device, and biotechnology studies in a range of therapeutic areas.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
